|
|
|
|
|
|
With over forty imaging modalities ordered over the last six months, scientists worldwide have come to appreciate the unique benefits of MILabs’ PET, SPECT, Optical, and CT techniques.
Selected new customers below illustrate the pent-up demand for the advanced applications enabled by MILabs imaging systems, whether used as stand-alone or as fully integrated multimodal systems.
|
|
|
Some reasons why MILabs’ systems are so popular:
|
|
|
|
|
User-friendly systems, reliable and easy to install, even remotely
|
|
|
MILabs systems can be installed in almost any lab, even remotely, as shown recently in Osaka, Japan, where an MILabs PET/SPECT/CT was swiftly installed, straight out-of-the-box. With the assistance of one local technician and remote access from an engineer from MILabs systems are quickly up and running.
|
|
|
|
Enjoy highly stable and quiet technology
|
|
|
|
Best of all, there are no special requirements for electricity, ambient temperature control, or availability of compressed air, since unlike solid-state PET and SPECT, MILabs systems do not depend on temperature-sensitive solid-state detectors. Even MILabs full combination with the four integrated modalities is really quiet, thus you are in accordance with animal protection and welfare protocols and also can flawlessly communicate with your colleagues, without wearing hearing protection. No more headaches after a day in the lab.
|
|
|
|
Now, you can image a mouse like a man
|
|
|
A straightway translation to the patient requires the ability to image a mouse with equivalent resolution as a human with a clinical scanner. The required 2000x better volumetric resolution (in micro-L) can only be achieved with an MILabs system – for all four modalities – including popular clinical PET isotopes with long positron ranges that were hereto unsuited for preclinical imaging such as 124I, 82Rb, and others. With 0.25mm SPECT resolution, 0.6mm for PET, 1.0mm for deep-tissue Optical Tomography, and 2.4 microns voxel resolution for CT imaging, MILabs’ systems outperform any other in-vivo system, no matter what modality, and regardless in what combination – even for single-pass acquisitions of all four modalities as illustrated (MIP image of PET/SPECT/Optical/CE-CT and segmented rendering for easy quantitation).
|
|
|
|
The power advantage of concurrent within-subject imaging
|
|
|
For the first time, it is feasible to perform quantitative studies that involve comparisons of disease conditions or the effect of treatments with a single acquisition of, e.g., a co-injected reference probe and a novel designed probe. Both molecular interactions will be co-registered in space and time. Direct comparison between PET/PET, PET/SPECT, and SPECT/SPECT probes are possible, with perfect spatial and temporal co-registration. As illustrated, this enables us to quantitatively decode 3D biology in real-time for both diagnostic and theranostic applications, even within the tumor microenvironment.
|
|
|
|
Seeing clearer and deeper in living tissue with Optical Tomography
|
|
|
MILabs 2D/3D optical imaging technology is gaining wide acceptance because of its superior performance and versatility for non-invasive monitoring and quantitation of bioluminescent and fluorescent reporters in living animals. Up to ten mice can be imaged simultaneously in 2D mode, but it’s the 3D optical tomography mode that entices many researchers using optical probes. By using CT-guided optical acquisitions to correct for the dissimilar light scattering and absorption in heterogeneous animal tissues, MILabs offers the only optical imager that is able to quantitate correctly the whole-body biodistributions of optical probes in-vivo.
|
|
|
|
Radiotherapy imaging: the straightway to the patient
|
|
|
The MILabs systems are capable to perform sub-mm resolution, high-energy and ultra-sensitive SPECT for many ⍺ and ß emitters used for radionuclide therapy. This avoids the need to use surrogate markers for internal dosimetry. Moreover, the high resolution for novel targeted alpha therapy (TAT) applications enables theranostic imaging of a mouse just like in a human. Despite the tiny size of a mouse as compared to a human, it is possible with MILabs systems to obtain in-vivo images of mice with the same intricate detail as can be obtained from scanning humans. The proprietary collimation technology enables imaging sub-mm resolutions up to 1 MeV.
|
|
|
|
The One and Only: Molecular imaging integrated with top-level diagnostic CT
|
|
|
|
Today, MILabs has achieved the long-term vision of higher-order multimodality imaging without compromising the performance of any of the modalities. A case in point is its diagnostic CT system. Through its unique autonomous gantry design, the X-ray CT system achieves exceptional performance in any configuration, whether stand-alone or fully integrated with PET, SPECT, and Optical modalities. It is simply the fastest ultra-high-resolution CT available today with the lowest radiation dose, and the ability for multi-gated acquisitions of single and multiple animals simultaneously. Moreover, it features dynamic acquisitions, dual-energy scanning, and the ability to acquire mouse, rat, guinea pig, ferret, and rabbit images. Plus, CE-CT and DCE-CT acquisitions are possible even with clinical contrast agents.
|
|
|
|
No matter what upgrade or expansion, the whole is greater than the sum of its parts
|
|
|
|
All MILabs modalities are expandable, in any combination, and at any time. One can start with the simplest module and add modalities later, in any combination, when the need arises. However, rather than simply adding extra separate modules, each module will work in synergy with those that all already present. Rather than additive, each new module will leverage the capabilities of already present modalities. This synergy between modalities is unique for MILabs multimodality system. You’ll go from 2D to 3D optical images by adding CT, perform 3D autoradiography and ⍺ and ß theranostics by adding SPECT, and with the addition of PET, perform in-vivo histochemistry and within-subject rather than between-subject treatment comparisons. The upside: fewer animals and better statistics.
|
|
|
|
Follow MILabs on social media
|
|
|
|
|
|
|
|
|
